The clinical application of MOID can be also useful for the treatment of non-dividing (e.g., senescent) cancer cells with low MAD2 expression that is resistant to microtubule inhibitors (e.g., paclitaxel and vincristine) as well as other cytotoxic and DNA damaging agents (cisplatin and γ-irradiation) [53]. This evidence concerns the gene MAD2L1 and cancer.